GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.
The Pharma Data
JUNE 2, 2022
Affinivax’s most advanced vaccine candidate (AFX3772) includes 24 pneumococcal polysaccharides plus two conserved pneumococcal proteins (compared to up to 20 serotypes in currently approved vaccines). A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. About Pneumococcal disease.
Let's personalize your content